Pharma M&A Deals 2025 – Top Themes: Strategic Intelligence
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report analyzes the disruptive themes that have driven M&A activity in 2025 in the pharma Sector.
Scope
This report provides an overview of merger and acquisition activity globally in 2025 in Pharma Sector
It identifies the themes driving most notable to deals announced in 2025 in the Pharma Sector
Key Highlights
The global pharma sector in 2025 witnessed deals worth $232 billion, a growth of 40% compared to 2024. The Pharma sector recorded deal value worth $199 billion mega deals (defined as any deal valued at more than $1 billion) in 2025, an increase of 67% compared to 2024.
Reasons to Buy
Companies who invest in the right themes become success stories; those who miss the big themes end up as failures. If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&A).
In this report we have listed down the most notable deals in pharma sector to make it easy for our clients to get a view of themes disrupting the sector and prepare for the future.
Abu Dhabi Investment Authority
Blackstone Inc
GIC Private Ltd
TPG Capital LP
Johnson & Johnson
Novartis AG
Merck & Co Inc
Sanofi
Thermo Fisher Scientific Inc
Merck & Co Inc
Genmab AS
Pfizer Inc
Exact Sciences Corp
Hologic Inc
Intra-Cellular Therapies Inc
Avidity Biosciences Inc
Verona Pharma Plc
Blueprint Medicines Corp
Clario
Cidara Therapeutics Inc
Merus NV
Metsera Inc
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745